A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Cirtuvivint (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Biosplice Therapeutics
- 09 Aug 2024 Status changed from active, no longer recruiting to discontinued due to business reasons by Sponsor.
- 17 Oct 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 17 Oct 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.